The U.S. Food and Drug Administration (FDA) approved nemolizumab in 2024 for treatment of moderate-to-severe atopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results